Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Visterra
MedTech
Otsuka to acquire antibody developer Visterra in $430M deal
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Conor Hale
Jul 11, 2018 10:47am
Vir allies with Alnylam, others to build infectious disease pipeline
Oct 18, 2017 7:01am
Visterra adds $24M to series C to take flu drug to phase 2b
Oct 5, 2017 8:57am
Visterra snags contract to start recovery from IPO misstep
Mar 30, 2017 11:05am
Tocagen seeks $86M IPO to fund cancer gene therapy trial
Mar 10, 2017 4:24am
